Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 with ADT in Newly Diagnosed Metastatic Prostate Cancer
NCT02582749Phase 2Terminated
- Start
- Apr 2016
- Primary completion
- Sep 2017
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of radium-223 dichloride in prostate cancer (PCa) (2 arms). Primary endpoint: Radiological Progression-Free Survival at 24 months. Started Apr 2016; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02582749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582749.